{"schema":"sb.node.v1","id":"sb:e/d269e792c2d08f1041a527eb","kind":"entity","label":{"text":"orphan drug","locale":"en"},"identity":{"anchor":"label:en:orphan drug","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T23:27:45.667496+00:00","snapshot":"deploy ca5d81785b2e8e9d3cb25b959dbaa72ddee4391e"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":47,"separatePublishers":17,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.085,"named":4,"of":47,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 9% of the 47 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-07-08","to":"2026-10-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.532: about 47% of mentions carry no typed assertion"]}},"dimensions":{"domains":["biotech_pharma","pharma-regulatory","rare_diseases","auto"],"activeDays":28,"assertions":{"regulatory-approval":18,"launch-release":4,"disaster":1,"acquisition":1,"meeting-visit":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":3,"byKind":{"observation":3},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/b87f0c38ebf2a8fc4ce03811","kind":"observation","label":"The Clinical Trial Vanguard · 2026-09-24 · FDA Approves Lyrfigtu for FGFR2-Rearranged Cholangiocarcinoma","url":"https://www.clinicaltrialvanguard.com/news/fda-approves-lyrfigtu-for-fgfr2-rearranged-cholangiocarcinoma/"},{"id":"sb:o/fcc5d614d7deb120b315a723","kind":"observation","label":"FDA · 2026-09-08 · Rare Diseases at FDA","url":"http://www.fda.gov/patients/rare-diseases-fda"},{"id":"sb:o/21fa1572657af4f8ebf67cd1","kind":"observation","label":"FDA Drug News · 2026-07-08 · Medical Products for Rare Diseases and Conditions","url":"http://www.fda.gov/industry/medical-products-rare-diseases-and-conditions"}],"cursor":null,"order":"newest first; we keep the 3 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (44 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3db9247a97708a915e2547eb"},{"kind":"relation","label":"co-mentioned with drug administration (21 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/69c1154f897685ab923afa34"},{"kind":"relation","label":"co-mentioned with priority review (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4614202196a42821c7aac647"},{"kind":"relation","label":"co-mentioned with breakthrough therapy (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/74c24d87a595a9fd08bf4a20"},{"kind":"relation","label":"co-mentioned with clinical trial (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9d110e276a0dc14b76620ea3"},{"kind":"relation","label":"co-mentioned with fda-approved (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/423071eab1e265c2ac6c578a"},{"kind":"relation","label":"co-mentioned with u.s. food (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3a446913d09e87c71eb80025"},{"kind":"relation","label":"co-mentioned with clinical trials (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/6bc7aa405cfd3bf20a0bbf9c"},{"kind":"relation","label":"co-mentioned with adverse events (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4e81cddf3695e8e64795c540"},{"kind":"relation","label":"co-mentioned with nasdaq (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f2d563aee4aed9233dfcdf53"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/d269e792c2d08f1041a527eb","mcp":"traverse {\"id\":\"sb:e/d269e792c2d08f1041a527eb\"}","page":"/entity/orphan-drug/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/d269e792c2d08f1041a527eb\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/d269e792c2d08f1041a527eb\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/d269e792c2d08f1041a527eb\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/d269e792c2d08f1041a527eb\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}